Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XN1F
|
|||
| Former ID |
DAP000306
|
|||
| Drug Name |
Nimodipine
|
|||
| Synonyms |
Admon; Brainal; Calnit; Kenesil; Modus; NimoGel; NimodipinISIS; Nimodipino; Nimodipinum; Nimotop; Periplum; Remontal; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Cantabria Brand of Nimodipine; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Nimodipin Hexal; Nimodipin ISIS; Nimodipino Bayvit; Vita Brand of Nimodipine; Bay-E 9736; DRG-0139; EG-1961; N-149; NIMOTOP (TN); Nimodipin-ISIS; Nimodipino [INN-Spanish]; Nimodipinum [INN-Latin]; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Bay-e-9736; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Periplum, Nimotop, BRN 0459792, DRG-0139; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3′-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cerebral vasospasm [ICD-11: BA85.Z; ICD-9: 443.9] | Approved | [1], [2] | |
| Therapeutic Class |
Vasodilator Agents
|
|||
| Company |
Bayer Pharmaceuticals Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H26N2O7
|
|||
| Canonical SMILES |
CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
|
|||
| InChI |
1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
|
|||
| InChIKey |
UIAGMCDKSXEBJQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 66085-59-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9476, 596563, 855566, 3153214, 4444853, 6951262, 7404101, 7847504, 7980128, 8152770, 11119999, 11120487, 11120975, 11121462, 11121942, 11147082, 11341987, 11362170, 11362531, 11364815, 11365093, 11367377, 11367655, 11369939, 11370333, 11370334, 11371732, 11373256, 11374401, 11375817, 11378106, 11466946, 11468066, 11485200, 11486721, 11487572, 11489378, 11490582, 11492606, 11495694, 11528721, 12013716, 14831516, 17405450, 24277858, 26612490, 26663021, 26680672, 26747118, 26747119
|
|||
| ChEBI ID |
CHEBI:7575
|
|||
| ADReCS Drug ID | BADD_D01569 | |||
| SuperDrug ATC ID |
C08CA06
|
|||
| SuperDrug CAS ID |
cas=066085594
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3] | |||
| Metabolic Reaction | Nitroreduction | |||
| Experimental Method | High-throughput screening | |||
| Description | Nimodipine can be metabolized by gut microbiota through nitroreduction. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Nimodipine (adjusted p-values: 9.61E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium channel unspecific (CaC) | Target Info | Blocker | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2523). | |||
| REF 2 | Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. | |||
| REF 3 | Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.